Global POC Diagnostics Market to Reach Nearly USD 90 Billion Due to Growing Demand for Rapid COVID-19 Test Kits
By LabMedica International staff writers Posted on 13 Dec 2021 |
The global point of care (POC) diagnostics market is estimated to grow at a CAGR of 12.7% from approximately USD 36 billion in 2021 to nearly USD 90 billion in 2028, driven by the increasing prevalence of infectious diseases, product developments and launches, and rise in the number of CLIA-waived POC tests. However, product recalls are expected to hamper market growth.
These are the latest findings of ResearchAndMarkets (Dublin, Ireland), the world’s largest market research store.
Point of care testing (POCT) is described as medical diagnostic testing at or near the point of care that is, at time and place of patient care. The purpose of POCT is to provide immediate information to physicians about the patient's condition. POCT is an important diagnostic tool used in various locations in the hospital such as the intensive care unit (ICU), the operating room (OR), and the emergency department (ED).
Based on product, the glucose monitoring segment held the largest share of the global POC diagnostics market in 2020. However, the infectious diseases segment is estimated to register the highest CAGR of 14.1% during the forecast period. The POC diagnostics market is witnessing substantial growth amid the COVID-19 pandemic. Certain factors such as sudden rise in coronavirus infections and exponential growth in COVID-19 diagnostic kits have played a prominent role in the growth of the POC diagnostics market during the pandemic. In addition, the growing demand for rapid COVID-19 test kits for faster diagnosis at public places is also estimated to have a positive impact on market growth.
Related Links:
ResearchAndMarkets
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus